Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

Cancer Treat Rep. 1978 Jan;62(1):1-11.


Evidence from the peritoneal dialysis literature suggests that the peritoneal permeability of a number of hydrophilic anticancer drugs may be considerably less than plasma clearance. Pharmacokinetic calculations indicate that such drugs administered ip in large volumes are expected to maintain a significantly greater concentration in the peritoneal space than in the plasma. This concentration difference offers a potentially exploitable biochemical advantage in the treatment of patients with presumed microscopic residual ovarian cancer confined to the peritoneal cavity.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / metabolism
  • Ascitic Fluid / metabolism
  • Cytarabine / administration & dosage
  • Cytarabine / metabolism
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Methotrexate / administration & dosage
  • Methotrexate / metabolism
  • Models, Biological
  • Ovarian Neoplasms / drug therapy*
  • Tissue Distribution


  • Antineoplastic Agents
  • Cytarabine
  • Methotrexate